Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. | Zendy

Fabrizio Tomai | Zendy; Filippo Crea | Zendy; Achille Gaspardone | Zendy; Francesco Versaci | Zendy; Ruggero De Paulis | Zendy; Alfonso Penta de Peppo | Zendy; Luigi Chiariello | Zendy; Pier Agostino Gioffrè | Zendy

Open Access

Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.

Author(s) -

Fabrizio Tomai,

Filippo Crea,

Achille Gaspardone,

Francesco Versaci,

Ruggero De Paulis,

Alfonso Penta de Peppo,

Luigi Chiariello,

Pier Agostino Gioffrè

Publication year - 1994

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.90.2.700

Subject(s) - glibenclamide , medicine , angioplasty , ischemic preconditioning , cardiology , ischemia , placebo , balloon , anesthesia , saline , diabetes mellitus , endocrinology , alternative medicine , pathology

Brief episodes of ischemia render the heart more resistant to subsequent ischemia; this phenomenon has been called ischemic preconditioning. In some animal species, myocardial preconditioning appears to be due to activation of ATP-sensitive K+ (KATP) channels. The role played by KATP channels in preconditioning in humans remains unknown. The aim of this study was to establish whether glibenclamide, a selective KATP channel blocker, abolishes the ischemic preconditioning observed in humans during coronary angioplasty following repeated balloon inflations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research